Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Ewing SarcomaRhabdomyosarcomaWilms TumorNeuroblastomaHepatoblastomaGerm Cell Tumor
Interventions
DRUG

Vorinostat

This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.

Trial Locations (1)

10595

RECRUITING

New York Medical College, Valhalla

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER

NCT04308330 - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | Biotech Hunter | Biotech Hunter